期刊文献+

头孢噻肟钠和头孢他美酯片序贯疗法治疗女性泌尿系统感染疗效观察 被引量:5

Switch Therapy with Cefotaxime Sodium and Cefetamet in Female Patients with Urinary Tract Infection
原文传递
导出
摘要 目的:评价头孢噻肟钠和头孢他美酯片序贯疗法治疗中~重度女性泌尿系统感染的疗效和安全性。方法:119例患者按住院号随机分为混合组和单用组。混合组先给予头孢噻肟钠3g+生理盐水100mL,静脉滴注,2次.d-1;治疗3d后改用头孢他美酯片250mg,口服,2次.d-1。疗程7~14d。单用组给予头孢噻肟钠3g+生理盐水100mL,静脉滴注,2次.d-1,治疗7~12d。结果:2组平均好转天数、痊愈率、有效率、细菌清除率比较无显著性差异(P>0.05),但平均费用混合组明显低于单用组(P<0.05)。结论:头孢噻肟钠和头孢他美酯片序贯疗法治疗中~重度女性泌尿系统感染安全、有效、经济。 OBJECTIVE: To evaluate the curative efficacy and safety of the switch therapy with Cefotaxime Sodium and cefetamet in the treatment of female patients with moderate to severe urinary tract infection.METHODS: A total of 119 cases were randomly divided into two groups according to their admission numbers:the combined therapy group was treated i.v.with cefotaxime(3 g) + NS(100 mL) b.i.d for 3days, followed by cefetamet tablets 250 nag per os b.i.d for 7 -14 days, while the single therapy group was treated i .v. with cefotaxime(3 g) + NS(100 mL) b .i .d alone for 7-12 days .RESULTS:There were no significant differences between two groups in average days of improvement, cure rates, effective rates and bacterial clearance rates(P 〉0.05), however, the average cost in combined group was significantly lower than in single group(P 〈 0.05) .CONCLUSION: The switch therapy with Cefotaxime Sodium and cefetamet was proved to be safe, economical and effective for moderate to severe infection of female urinary system.
出处 《中国药房》 CAS CSCD 北大核心 2008年第5期362-363,共2页 China Pharmacy
关键词 头孢噻肟钠 头孢他美酯 序贯疗法 泌尿系统感染 Cefotaxime sodium Cefetamet Switch therapy Urinary system infection
  • 相关文献

参考文献4

二级参考文献13

  • 1叶煜荣.经营药剂科[J].中国处方药,2002,1(1):71-71. 被引量:4
  • 2[1]Grasela DM. Clinical pharmacology of gatifloxacin, a new fluoroquinolone[J]. Clin Infect Dis, 2000, 31(Suppl 2): S51-58
  • 3[2]Perry CM, Ormrod D, Hurst M, et al. Gatifloxacin: a review of its use in the management of bacterial infections[J]. Drugs, 2002, 62: 169-207
  • 4[3]Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults[J]. Clin Infect Dis, 2000, 31: 347-382
  • 5[4]Niederman MS, Momdell CA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention[J]. Am J Respir Crit Care Med, 2001, 163: 1730-1754
  • 6[5]Pankuch GA, Jacobs MR, Appelbaum PC. Postantibiotic effects of gatifloxacin against Gram-positive and negative organisms[J]. Antimicrob Agents Chemother, 1999, 43: 2574-2575
  • 7[6]Sullivan JG, McElroy AD, Honsinger RW, et al. Treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin[J]. J Respir Dis, 1999, 20(suppl): S49-S59
  • 8[7]Breen J, Skuba K, Grasela D. Safety and tolerability of gatifloxacin, an advanced-generation, 8-methoxy fluoroquinolone[J]. J Respir Dis, 1999, 20(suppl): s70-s75
  • 9[1]Cullmann W, Edwards DJ, Kissling M,et al. Cefetamet pioil:a review of its microbiology, toxicology, pharmacokinetics and clinical efficacy. Int J Antimicrob Agents, 1992,175
  • 101,Elliott M. Ceftibuten as stepdowntherapy after parenteral third genera tion cephalosporin treatment for serious infection.Abstract presented at the 19 th International Congress of Chemotherapy,Monlreal,Quebes.Canada.1993

共引文献108

同被引文献54

引证文献5

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部